Severe dementia: A review on diagnoses, therapeutic management and ethical issues;Demência grave: Uma revisão sobre diagnóstico, manejo terapêutico e ético

Dementia e Neuropsychologia

Volumn 4, Issue 3, 2010, Pages 158-164

  Schafrovits Morillo, Lilian ^a   Suemoto, Cláudia Kimie ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Alzheimer's disease; Dementia; Severe

Indexed keywords

EID: 77958134526     PISSN: 19805764     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1980-57642010dn40300003     Document Type: Article

References (32)

1. Schmitt FA, Wichems CH. A systematic review of assessment and treatment of moderate to severe Alzheimer's disease. J Clin Psychiatry 2006; 8:158-159.
2. Herrmann N, Gauthier S. Diagnosis and treatment of de mentia: 6. Management of severe Alzheimer's disease. CMAJ 2008; 179:1279-1287.
3. Larson EB, Shadlen MF, Wang L, et al. Survival after initial diagnosis of Alzheimer disease. Ann Intern Med 2004; 140:501-509.
4. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198.
5. Saxton J, McGonigle-Gibson KL, Swihart AA, et al. Assessment of the severely impaired patient: description and validation of a new neuropsychological test battery. Psychol Assess 1990; 2:298-303.
6. Reisberg B, Doody R, Stoffer A, et al. Memantina in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348: 1333-1341.
7. Reiberg B. Functional Assessment Staging (FAST). Psychop-harmacol Bull 1988; 24:653-659.
8. Reisberg B, Ferris SH, Leon MJ, et al. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139:1136-1139.
9. Morris, JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43:2412-2414.
10. Harrell LE. The Severe Mini-Mental State Examination: a new neuropsychologic instrument for the bedside assessment of severely impaired patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2000; 14:168-175
11. Nitrini R, Lefèvre BH, Mathias SC, et al. Testes neuropsi cológicos de aplicação simples para o diagnóstico de demên-cia. Arq Neuropsiquiatr 1994; 52:457-465.
12. Cumming J, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatry Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44:2308-2314.
13. Alexopoulos GS, Abrams RC, Younge RC, Shamoian CA: Cornell Scale for Depression in Dementia. Biol Psychiatry 1988; 23:271-284.
14. Tariot PN. Medical management of advanced dementia. J Am Geriatr Soc 2003; 51:S305-S313.
15. Tariot PN. Treatment of agitation in dementia. J Clin Psychiatry 1999; 60(Suppl.):11-20.
16. Verkaik R, van Weert JC, Francke AL. The effects of psychosocial methods on depressed, aggressive and apathetic behaviors of people with dementia: a systematic review. Int J Geriatr Psychiatry 2005; 20:301-314.
17. Livingston G, Johnston K, Katona C, et al. Systematic review of psychological approaches to the management of neuro psychiatric symptoms of dementia. Am J Psychiatry 2005; 162:1996-2021.
18. Gauthier S, Cummings J, Ballard C, et al. Management of behavioral problems in Alzheimer's disease. Int Psychogeriatr 2010; 22:346-372.
19. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934-1943.
20. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications N Engl J Med 2005; 353:2335-2341.
21. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia. JAMA 2005; 293:596-608.
22. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001; 57:613-620.
23. Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the effcacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001; 49:1590-1599.
24. Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005; 21:1317-1327.
25. Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006; 367:1057-1065.
26. Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer's disease. Neurology 2007; 69:459-469.
27. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Co-chrane Database Syst Rev 2006; 25:CD005593.
28. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Beneft and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999; 14:135-146.
29. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe dementia already receiving donepezil: a randomized controlled trial. JAMA 2004; 291:317-324.
30. Jones RW, Bayer A, Inglis F, et al. Safety and tolerability of once-daily versus twice-daily memantine: a randomized, double-blind study in moderate to severe Alzheimer's disease. Int J Geriatr Psychiatry 2007; 22:258-262.
31. Livingston G, Katona C. The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis. Int J Geriatr Psychiatry 2005; 20:459-464.
32. Shuster J Jr. Palliative Care for Advanced Dementia. Clin Geriatr Med. 16: 373-86, 2000.